Celldex Therapeutics (CLDX) Current Leases (2019 - 2026)
Celldex Therapeutics (CLDX) posted quarterly Current Leases of $1.5 million for Q1 2026, down 2.27% year-over-year from $1.5 million in Q1 2025, and down 5.61% quarter-over-quarter from $1.6 million in Q4 2025.
Celldex Therapeutics (CLDX) Current Leases (2019 - 2026) Analysis & Trends
Celldex Therapeutics' Current Leases history runs 8 years deep, the most recent figure standing at $1.5 million for Q1 2026.
- In Q1 2026, Current Leases fell 2.27% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $1.5 million (down 2.27% YoY), while the FY2025 annual figure was $1.6 million, up 6.89% from the prior year.
- Current Leases for Q1 2026 stood at $1.5 million, down from $1.6 million in the prior quarter.
- The five-year high for Current Leases was $1.8 million in Q1 2022, with the low at $1.4 million in Q3 2024.
- The 5-year median for Current Leases is $1.5 million (2023), against an average of $1.5 million.
- Peak annual rise in Current Leases reached 31.34% in 2022, while the deepest fall reached 17.24% in 2022.
- Celldex Therapeutics' Current Leases stood at $1.4 million in 2022, then grew by 11.7% to $1.6 million in 2023, then retreated by 10.04% to $1.5 million in 2024, then increased by 6.89% to $1.6 million in 2025, then dropped by 5.61% to $1.5 million in 2026.
- Business Quant data shows CLDX's Current Leases at $1.5 million in Q1 2026, $1.6 million in Q4 2025, and $1.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Celldex Therapeutics | 3.29 Bn | 2.58 Bn | -2.57 Mn | 1.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.56 Mn |
| Mar 31, 2026 | 1.47 Mn |
| Dec 31, 2025 | 1.55 Mn |
| Sep 30, 2025 | 1.55 Mn |
| Jun 30, 2025 | 1.54 Mn |
| Mar 31, 2025 | 1.50 Mn |
| Dec 31, 2024 | 1.45 Mn |
| Sep 30, 2024 | 1.38 Mn |
| Jun 30, 2024 | 1.59 Mn |
| Mar 31, 2024 | 1.64 Mn |
| Dec 31, 2023 | 1.61 Mn |
| Sep 30, 2023 | 1.55 Mn |
| Jun 30, 2023 | 1.53 Mn |
| Mar 31, 2023 | 1.49 Mn |
| Dec 31, 2022 | 1.45 Mn |
| Sep 30, 2022 | 1.44 Mn |
| Jun 30, 2022 | 1.43 Mn |
| Mar 31, 2022 | 1.80 Mn |
| Dec 31, 2021 | 1.75 Mn |
| Sep 30, 2021 | 1.37 Mn |